Red Script Ventures : Another addition to Johnson & Johnson's early stage R&D tool-box

Red Script is a business accelerator whose purpose is to make early stage investments--either seed or Series A-- in companies developing riskier, but potentially transformative-types of science, such as regenerative medicine or neurostimulation.

With product pipelines at major pharmaceutical companies under pressure but budgets tight, drug makers are increasingly interested in extending their R&D bandwidth without taking on the risk—and more importantly cost—of additional infrastructure. Virtual R&D—via corporate venturing, business development alliances, project financing, incubators or some combination thereof--is the new reality. (See "New Frontiers in Pharma R&D Investment," IN VIVO , November 2009 Also see "New Frontiers in Pharma R&D Investment" - In Vivo, 1 November, 2009..)

Perhaps no health care company has been more externally focused than Johnson & Johnson, which has been talking up...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

Novartis’s Cosentyx Suffers Rare Phase III Fail

 
• By 

Multi-blockbuster falls short in a giant cell arteritis study.

In Brief: BioVersys And Shionogi Align In Non-Tuberculous Mycobacteria R&D

 
• By 

Deal Snapshot: Having recently raised an $89m IPO, BioVersys is partnering on and optioning rights to a preclinical NTM development program with Shionogi.

BerGenBio Plumps For Oncoinvent From Long List Of 50 Suitors

 
• By 

The merger with a fellow Norwegian biotech comes a few months after its lead asset, bemcentinib, bit the dust.

Protagonist Hopes To Come From Behind In Obesity With Oral Triple Agonist

 

The company announced plans to move an oral GLP-1/GIP/GCG receptor agonist peptide into clinical development for obesity in 2026.

More from Business

Protagonist Hopes To Come From Behind In Obesity With Oral Triple Agonist

 

The company announced plans to move an oral GLP-1/GIP/GCG receptor agonist peptide into clinical development for obesity in 2026.

In Brief: Sanofi Cements Support For Adagene

 
• By 

Deal Snapshot: The French drugmaker has been shifting its investments away from cancer to focus on immunology and inflammation but it continues to seek out interesting early-stage oncology assets.

In Vivo CAR-T Interest Grows With AbbVie Acquisition

 

Acquiring Capstan gives AbbVie a stake in two competing in vivo CAR-T delivery platforms, with the field's first readouts expected in 2026.